These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 12236624)

  • 21. Dopamine (D2/3) receptor agonist positron emission tomography radiotracer [11C]-(+)-PHNO is a D3 receptor preferring agonist in vivo.
    Narendran R; Slifstein M; Guillin O; Hwang Y; Hwang DR; Scher E; Reeder S; Rabiner E; Laruelle M
    Synapse; 2006 Dec; 60(7):485-95. PubMed ID: 16952157
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Simultaneous in-vivo receptor occupancy assays for serotonin 1A, 2A, and dopamine 2 receptors with the use of non-radiolabelled tracers: Proposed method in screening antipsychotics.
    Thentu JB; Nirogi R; Bhyrapuneni G; Ajjala DR; Aleti RR; Palacharla RC
    J Pharmacol Toxicol Methods; 2017; 85():22-28. PubMed ID: 28063918
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vivo vulnerability to competition by endogenous dopamine: comparison of the D2 receptor agonist radiotracer (-)-N-[11C]propyl-norapomorphine ([11C]NPA) with the D2 receptor antagonist radiotracer [11C]-raclopride.
    Narendran R; Hwang DR; Slifstein M; Talbot PS; Erritzoe D; Huang Y; Cooper TB; Martinez D; Kegeles LS; Abi-Dargham A; Laruelle M
    Synapse; 2004 Jun; 52(3):188-208. PubMed ID: 15065219
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of risperidone on high-affinity state of dopamine D2 receptors: a PET study with agonist ligand [11C](R)-2-CH3O-N-n-propylnorapomorphine.
    Kodaka F; Ito H; Takano H; Takahashi H; Arakawa R; Miyoshi M; Okumura M; Otsuka T; Nakayama K; Halldin C; Farde L; Suhara T
    Int J Neuropsychopharmacol; 2011 Feb; 14(1):83-9. PubMed ID: 20860881
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modeling of brain D2 receptor occupancy-plasma concentration relationships with a novel antipsychotic, YKP1358, using serial PET scans in healthy volunteers.
    Lim KS; Kwon JS; Jang IJ; Jeong JM; Lee JS; Kim HW; Kang WJ; Kim JR; Cho JY; Kim E; Yoo SY; Shin SG; Yu KS
    Clin Pharmacol Ther; 2007 Feb; 81(2):252-8. PubMed ID: 17259948
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Occupancy of agonist drugs at the 5-HT1A receptor.
    Bantick RA; Rabiner EA; Hirani E; de Vries MH; Hume SP; Grasby PM
    Neuropsychopharmacology; 2004 May; 29(5):847-59. PubMed ID: 14985704
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A PET-study of [11C]FLB 457 binding to extrastriatal D2-dopamine receptors in healthy subjects and antipsychotic drug-treated patients.
    Farde L; Suhara T; Nyberg S; Karlsson P; Nakashima Y; Hietala J; Halldin C
    Psychopharmacology (Berl); 1997 Oct; 133(4):396-404. PubMed ID: 9372541
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Actions of novel antipsychotic agents on apomorphine-induced PPI disruption: influence of combined serotonin 5-HT1A receptor activation and dopamine D2 receptor blockade.
    Auclair AL; Kleven MS; Besnard J; Depoortère R; Newman-Tancredi A
    Neuropsychopharmacology; 2006 Sep; 31(9):1900-9. PubMed ID: 16421514
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Delayed normalization of central D2 dopamine receptor availability after discontinuation of haloperidol decanoate. Preliminary findings.
    Nyberg S; Farde L; Halldin C
    Arch Gen Psychiatry; 1997 Oct; 54(10):953-8. PubMed ID: 9337776
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The cataleptogenic effects of the neuroleptic nemonapride are attenuated by its 5-HT1A receptor agonist properties.
    Prinssen EP; Kleven MS; Koek W
    Eur J Pharmacol; 1998 Sep; 356(2-3):189-92. PubMed ID: 9774248
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vivo occupancy of the 5-HT1A receptor by a novel pan 5-HT1(A/B/D) receptor antagonist, GSK588045, using positron emission tomography.
    Comley RA; van der Aart J; Gulyás B; Garnier M; Iavarone L; Halldin C; Rabiner EA
    Neuropharmacology; 2015 May; 92():44-8. PubMed ID: 25476970
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man--a PET study with [11C]raclopride.
    Vollenweider FX; Vontobel P; Hell D; Leenders KL
    Neuropsychopharmacology; 1999 May; 20(5):424-33. PubMed ID: 10192823
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Estimation of the time-course of dopamine D2 receptor occupancy in living human brain from plasma pharmacokinetics of antipsychotics.
    Takano A; Suhara T; Ikoma Y; Yasuno F; Maeda J; Ichimiya T; Sudo Y; Inoue M; Okubo Y
    Int J Neuropsychopharmacol; 2004 Mar; 7(1):19-26. PubMed ID: 14764214
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients.
    Nordström AL; Farde L; Wiesel FA; Forslund K; Pauli S; Halldin C; Uppfeldt G
    Biol Psychiatry; 1993 Feb; 33(4):227-35. PubMed ID: 8097114
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is amoxapine an atypical antipsychotic? Positron-emission tomography investigation of its dopamine2 and serotonin2 occupancy.
    Kapur S; Cho R; Jones C; McKay G; Zipursky RB
    Biol Psychiatry; 1999 May; 45(9):1217-20. PubMed ID: 10331115
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Positron emission tomographic evaluation of the putative dopamine-D3 receptor ligand, [11C]RGH-1756 in the monkey brain.
    Sóvágó J; Farde L; Halldin C; Langer O; Laszlovszky I; Kiss B; Gulyás B
    Neurochem Int; 2004 Oct; 45(5):609-17. PubMed ID: 15234102
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PET evidence that loxapine is an equipotent blocker of 5-HT2 and D2 receptors: implications for the therapeutics of schizophrenia.
    Kapur S; Zipursky R; Remington G; Jones C; McKay G; Houle S
    Am J Psychiatry; 1997 Nov; 154(11):1525-9. PubMed ID: 9356559
    [TBL] [Abstract][Full Text] [Related]  

  • 38. N-[11C]methylspiperone PET, in contrast to [11C]raclopride, fails to detect D2 receptor occupancy by an atypical neuroleptic.
    Hagberg G; Gefvert O; Bergström M; Wieselgren IM; Lindström L; Wiesel FA; Långström B
    Psychiatry Res; 1998 Jun; 82(3):147-60. PubMed ID: 9754439
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vivo drug action of tandospirone at 5-HT1A receptor examined using positron emission tomography and neuroendocrine response.
    Nakayama T; Suhara T; Okubo Y; Ichimiya T; Yasuno F; Maeda J; Takano A; Saijo T; Suzuki K
    Psychopharmacology (Berl); 2002 Dec; 165(1):37-42. PubMed ID: 12474116
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Error analysis for PET measurement of dopamine D2 receptor occupancy by antipsychotics with [11C]raclopride and [11C]FLB 457.
    Ikoma Y; Ito H; Arakawa R; Okumura M; Seki C; Shidahara M; Takahashi H; Kimura Y; Kanno I; Suhara T
    Neuroimage; 2008 Oct; 42(4):1285-94. PubMed ID: 18585466
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.